Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / People / Jennifer Buell
Person

Jennifer Buell

Tracked across 2 events · 18 articles · First seen Apr 03, 2026 · Last active May 28, 2026

Sentiment
45
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
4 60
Tech
MiNK Therapeutics Doses First Patient
MiNK Therapeutics announced the dosing of the first patient in its randomized Phase 2 clinical trial (C-1300-02) evaluating agenT-797 for severe acute lung injury and critical illness. The trial, conducted in collaboration with First Lviv…
Impact: As President and CEO of MiNK Therapeutics, Jennifer Buell's statements highlight the importance of this clinical trial for critical illness, reinforcing the company's commitment to addressing unmet medical needs.
May 28, 2026 · 6 articles
4 30
Tech
MiNK Therapeutics agenT-797 Phase II Data
Impact: Jennifer Buell, President and CEO of MiNK Therapeutics, provided commentary on the positive trial results and the potential of agenT-797.
Apr 03, 2026 · 12 articles
NEWSDESK
Track Jennifer Buell live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.